Jan Van Rornout Biography and Net Worth

Dr. Jan Marie-Albert Van Tornout M.D., M.Sc. is the Chief Medical Officer at Tyme Technologies Inc.

What is Jan M. Van Rornout's net worth?: The estimated net worth of Jan M. Van Rornout is at least $409.19 as of April 7th, 2021. Dr. Van Rornout owns 1,317 shares of Tyme Technologies stock worth more than $409 as of April 19th. This net worth approximation does not reflect any other investments that Dr. Van Rornout may own. Learn More about Jan M. Van Rornout's net worth.
How do I contact Jan M. Van Rornout?: The corporate mailing address for Dr. Van Rornout and other Tyme Technologies executives is 17 STATE STREET 7TH FLOOR, NEW YORK NY, 10004. Tyme Technologies can also be reached via phone at (212) 461-2315 and via email at [email protected]. Learn More on Jan M. Van Rornout's contact information.
Has Jan M. Van Rornout been buying or selling shares of Tyme Technologies?: Jan M. Van Rornout has not been actively trading shares of Tyme Technologies during the last ninety days. Learn More on Jan M. Van Rornout's trading history.
Who are Tyme Technologies' active insiders?: Tyme Technologies' insider roster includes James Biehl (Insider), David Carberry (Director), Michael Demurjian (Major Shareholder), Barbara Galaini (Insider), Steve Hoffman (Insider), and Jan Van Rornout (Insider). Learn More on Tyme Technologies' active insiders.

Jan M. Van Rornout Insider Trading History at Tyme Technologies

Jan M. Van Rornout Buying and Selling Activity at Tyme Technologies

Tyme Technologies Company Overview

Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also developing TYME-19, an oral synthetic member of the bile acid family, which is in preclinical stage for the treatment of SARS CoV-2 diseases; and TYME-18, a CMBT compound that is in preclinical stage for the treatment of inoperable tumors. It has research collaborations with Mayo Clinic to perform in-depth analysis of pancreatic cancer cell gene expression, epigenetic, and metabolism changes from SM-88 treatment; and a research investigator at Georgetown University to examine the effects of SM-88 in breast cancer. The company was formerly known as Global Group Enterprises Corp. The company was incorporated in 2011 and is headquartered in Bedminster, New Jersey.

Today's Range

Now: $0.31

$0.29

$0.32

50 Day Range

MA: $0.30

$0.24

$0.35

2 Week Range

Now: $0.31

$0.22

$1.14

Volume

2,678,186 shs

Average Volume

1,009,732 shs

Market Capitalization

$53.50 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.93

Biden’s $374B Giveaway Into This Sector

From DTI | Ad

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story